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A mouse cytomegalovirus (MCMV) gene conferring interferon (IFN) resistance was 
identified. This gene, 
 
M27
 
, encodes a 79-kD protein that selectively binds and down-
regulates for signal transducer and activator of transcription (STAT)-2, but it has no effect 
on STAT1 activation and signaling. The absence of pM27 conferred MCMV susceptibility to 
type I IFNs (
 
 
 
/
 
 
 
), but it had a much more dramatic effect on type II IFNs (
 
 
 
) in vitro and in 
vivo. A comparative analysis of 
 
M27
 
 
 
 and 
 
M27
 
 
 
 MCMV revealed that the antiviral 
efficiency of IFN-
 
 
 
 was partially dependent on the synergistic action of type I IFNs that 
required STAT2. Moreover, STAT2 was directly activated by IFN-
 
 
 
. This effect required IFN 
receptor expression and was independent of type I IFNs. IFN-
 
 
 
 induced increasing levels of 
tyrosine-phosphorylated STAT2 in 
 
M27
 
 
 
 
 
MCMV-infected cells that were essential for the 
antiviral potency of IFN-
 
 
 
. pM27 represents a new strategy for simultaneous evasions from 
types I and II IFNs, and it documents an unknown biological significance for STAT2 in 
antiviral IFN-
 
 
 
 responses.
 
IFNs represent a major line of defense against
viruses connecting innate and adaptive immu-
nity. IFNs are classified into two distinct types:
type I (
 
 
 
/
 
 
 
) and type II (
 
 
 
). Type I IFNs are
synthesized in direct response to an infection
with a virus. IFN-
 
 
 
 is encoded by a multigene
family and is predominantly synthesized by
leukocytes. In contrast, the product of the
IFN-
 
 
 
 gene is produced by most cell types, in
particular by fibroblasts. IFN-
 
 
 
 is produced by
activated T lymphocytes and NK cells in re-
sponse to the recognition of virus-infected
cells. The binding of IFN-
 
 
 
/
 
 
 
 and IFN-
 
 
 
 to
their cognate transmembrane receptors initiates
distinct JAK-STAT–dependent signaling path-
ways (1, 2). The IFN
 
  
 
/
 
 
 
 receptor (IFNAR)
is composed of two subunits, IFNAR1 and
IFNAR2. Upon ligand binding, receptor-associ-
ated TYK2 and JAK1 are activated and phos-
phorylate STAT2, which allows for the recruit-
ment of STAT1 (3). Phosphorylated STAT1/
STAT2 heterodimers are translocated to the
nucleus and associate with the DNA-binding
protein p48 to form the heterotrimeric IFN-
stimulated gene factor 3 (ISGF3) complex,
which binds to IFN-stimulated response ele-
ment (ISRE) sequences of IFN-
 
 
 
/
 
 
 
–inducible
genes (1, 3). IFN-
 
 
 
 receptors (IFNGRs) consist
of IFNGR1 and IFNGR2, which are associated
with JAK1 and JAK2, respectively (4). IFNGR
triggering results in the formation of paired
binding sites for STAT1. STAT1 homodimers
translocate to the nucleus where they bind to
 
 
 
-activated sequence (GAS) elements to activate
transcription of IFN-
 
 
 
–inducible genes. Al-
though functional similarities between types I
and II IFNs exist, the systems are not redundant
with respect to the induction of specific genes
and the control of certain virus infections.
CMVs constitute prototypes of the 
 
 
 
-herpes-
viruses;  human CMV (HCMV) and mouse
CMV (MCMV) share a similar pathobiology
and have collinear genomes. Cellular immu-
nity and IFNs play prominent roles in CMV
immune control (5–7). Specifically, IFN-
 
 
 
 is
essential for the control of MCMV replication
in the salivary glands (SGs) and the effector
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function of CD8
 
 
 
 T cells in vivo (5, 8). CMV genes affect-
ing host immune functions increase the available time win-
dow for replication and facilitate virus shedding (9). The fail-
ure of infected cells to respond to both types of IFNs
suggested that CMVs disrupt IFN receptor (IFNR) signaling
by unknown gene functions (8, 10-12). We report on the
identification and characterization of the first cytomegalovi-
ral IFN response antagonist. To search for genes that disrupt
IFN signaling, we pursued a systematic approach by con-
structing IFN-responsive, ISRE-reporting cell lines suitable
for subsequent phenotypic screening with an MCMV
Tn
 
Max
 
16-transposon insertion library. The discovered gene,
 
M27
 
, encoding a 79-kD protein, proved to be an inhibi-
tor of both IFNAR- and IFNGR-mediated responses. The
viral inhibitor down-regulated STAT2 exclusively, whereas
STAT1-dependent functions remained unaffected. The dra-
matically increased susceptibility of 
 
 
 
M27-MCMV replica-
tion to IFN-
 
 
 
 was dependent on IFN-
 
 
 
 secretion, IFNAR
signaling, and STAT2 activation; this demonstrated a syner-
gistic action of type I IFNs with IFN-
 
 
 
. In addition, STAT2
was found to be directly activated by IFN-
 
 
 
 in the absence
of type I IFN responses. The findings document a direct, as
well as an indirect, augmentation of IFNGR responses via
STAT2 as a prerequisite for efficient antiviral gene expres-
sion in response to IFN-
 
 
 
.
 
RESULTS
Identification of MCMV 
 
M27
 
 as a candidate gene affecting 
ISRE-dependent gene expression
 
To monitor viral functions affecting IFN-inducible tran-
scription throughout the CMV replication cycle, we gener-
ated a reporter cell line expressing the luciferase gene under
the control of an ISRE-dependent promoter. The 3T3-
ISRE-luc cells responded to IFN-
 
 
 
 in a dose-dependent
manner over a range of 3–4 log
 
10
 
 steps of IFN concentration.
After infection, the IFN-
 
 
 
–induced, ISRE-dependent lu-
ciferase activity continuously declined and was abolished 36 h
p.i. (Fig. 1 A). This effect required MCMV gene expres-
sion because UV-inactivated MCMV was not capable of
mediating this inhibition. In the presence of the CMV poly-
merase inhibitor phosphonoacetic acid (PAA), we observed
a substantial inhibition of the IFN-
 
 
 
 response, which indi-
cated that MCMV E gene expression was required to block
the IFN-
 
 
 
 response. To identify the MCMV gene products
responsible for this inhibition, we used a forward genetic
procedure based on a random, single Tn insertion mutagen-
esis of the MCMV genome cloned as a bacterial artificial
chromosome BAC (13). 3T3-ISRE-luc cells were infected
with a large panel of reconstituted Tn
 
Max
 
16 containing
MCMV BAC mutants and tested for an IFN-
 
 
 
–induced lu-
ciferase expression. Although the bulk of MCMV mutants
were able to suppress the IFN-
 
 
 
–stimulated luciferase ex-
pression, three independent mutants failed to suppress the
response. The Tn
 
Max
 
16 insertion site in all three mutants
was mapped to the 
 
M27
 
 gene, which is dispensable for repli-
cation in vitro but plays an important role in growth and vir-
ulence in mice (14).
We constructed a targeted mutant with a complete dele-
tion of 
 
M27
 
 (
 
 
 
M27-MCMV) and a revertant virus (M27rev)
in which the 
 
M27
 
 open reading frame was reinserted into
the 
 
 
 
M27-MCMV genome. In contrast to 
 
 
 
M27-MCMV,
the MCMV-WT and M27rev almost completely inhibited the
IFN-
 
 
 
–induced ISRE response at 29 h p.i. (Fig. 1 B). An
MCMV mutant expressing a hemagglutinin (HA)-tagged
M27 protein (M27-HA) was constructed to determine the
kinetics of M27 protein expression. The 79-kD M27 protein
Figure 1. Inhibition of IFN- –dependent luciferase induction by 
MCMV M27. (A) 3T3-ISRE-luc cells were infected with 10 PFU/cell 
MCMV-WT strain Smith and stimulated with 500 U/ml IFN-  for 5 h at the 
indicated time points p.i. Results were expressed as the percentage of 
luciferase activity in comparison with uninfected cells. The influence of viral 
gene expression was studied by the analysis of luciferase activity in the 
presence of PAA, which inhibits the expression of viral late gene expression, 
and by the analysis of UV-inactivated virus (IAV). (B) 3T3-ISRE-luc cells 
were infected with MCMV-WT,  M27-MCMV, or M27rev (10 PFU/cell 
each) and stimulated with 500 U/ml IFN-  for 5 h at 8 h (mock) or 29 h 
(MCMV-WT and  M27-MCMV) p.i. Luciferase activity was determined 
luminometrically as relative light units (RLU). Each value represents the 
mean   SD from three independent experiments. (C) Expression kinetics 
of the M27 protein. MEFs were infected with 10 PFU/cell M27HA, and cell 
lysates were prepared at the indicated time points. Equivalent amounts of 
lysate were subjected to SDS-PAGE and then immunoblotted using anti-
HA antibodies. The selective synthesis of MCMV IE proteins was achieved 
by infecting cells in the presence of 50  g/ml of cycloheximide, which was 
then replaced by 5  g/ml of actinomycin for a further 2 h. 250  g/ml PAA 
was used to inhibit late phase gene expression. 
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(pM27) was detected 4 h p.i. and reached a maximal abun-
dance at 24 h p.i. pM27 was not recovered under conditions
of selective IE gene expression (Fig. 1 C). The viral polymer-
ase inhibitor PAA decreased pM27 synthesis, indicating a
typical early–late pattern of MCMV gene expression compat-
ible with the time course of the MCMV-induced inhibition
of ISRE-dependent transcription.
 
M27
 
 confers resistance of MCMV replication against type I 
and type II IFNs
 
To prove that the candidate gene 
 
M27
 
 is causally related to
IFN-induced cellular functions, a multistep replication anal-
ysis was performed. Primary C57BL/6 mouse embryonal fi-
broblasts (MEFs) pretreated with IFN-
 
 
 
 and IFN-
 
 
 
 for 48 h
before infection revealed a 5- and a 50-fold decrease, respec-
tively, of MCMV-WT replication by 96 h p.i. (Fig. 2 A),
confirming earlier results that demonstrated the moderate ef-
fect of IFNs in inhibiting the growth of MCMV in fibro-
blasts (11). In contrast, the replication of 
 
 
 
M27-MCMV
yielded 20-fold lower titers by IFN-
 
 
 
 at 96 h p.i., confirm-
ing an enhanced antiviral effect. Most strikingly, a much
more dramatic effect was observed with 500 U/ml IFN-
 
 
 
,
which inhibited 
 
 
 
M27-MCMV replication almost com-
pletely by four orders of magnitude (Fig. 2 A). The reintro-
duction of 
 
M27
 
 into the 
 
 
 
M27 genome (
 
M27
 
rev) restored
the MCMV-WT phenotype against both IFNs. An in-
creased sensitivity of 
 
 
 
M27-MCMV versus 
 
M27
 
rev was ob-
served at concentrations as low as 3 U/ml IFN-
 
 
 
 (Fig. 2 B),
confirming different dose responses for both viruses. In sum-
mary, the data proved that 
 
M27
 
 acts antagonistic to both
IFN-
 
 
 
 and IFN-
 
 
 
.
 
pM27 down-regulates STAT2
 
To gain insight into the molecular mechanism of the pM27-
dependent inhibition, we analyzed the overall levels of
STAT molecules in cells infected with MCMV-WT, 
 
 
 
M27-
MCMV, and M27HA STAT2 was strongly down-regulated
at 24 h p.i. (Fig. 3 A) and undetectable 48 h p.i in MCMV-
WT– and M27rev-infected cells (unpublished data). In con-
trast, STAT2 was abundantly present in cells infected with
the 
 
 M27-MCMV mutant. STAT2 mRNA was detected
in equal amounts in Northern blots of MCMV-WT– and
 M27-MCMV–infected cells (unpublished data), indicating
intact STAT2 gene transcription in M27-expressing cells.
Figure 2. Inhibition of  M27-MCMV replication by IFN-  and 
IFN- . (A) Primary C57BL/6-MEFs were infected with MCMV-WT,  M27-
MCMV, and M27rev (0.01 PFU/cell each). Titers of infectious virus were de-
termined by a standard plaque assay. Growth curves were obtained after 48 h 
of preincubation of cells without IFN, 500 U/ml IFN- , or 500 U/ml IFN- . 
(B) C57BL/6-MEFs were treated with graded concentrations of IFN-  and 
infected as in A with MCMV-WT and  M27-MCMV (0.01 PFU/cell each). 
Viral titers obtained at 96 h p.i. were shown in relation to doses of IFN- .
Figure 3. pM27 selectively affects STAT2. (A) pM27 down-regulates 
STAT2. C57BL/6-MEFs were either mock infected or infected with MCMV-WT, 
 M27-MCMV, or M27HA (10 PFU/cell each) for 24 h. Equivalent amounts 
of cell lysates were subjected to SDS-PAGE and analyzed by Western blot 
for STAT2, STAT1, IRF9/p48, IRF1, MCMV IE1/pp89, and  -actin. (B) NIH 
3T3 were either mock infected, infected with VV-WT as a control, or 
infected with rVVM27FL (5 PFU/cell each). Cell lysates were prepared 16 h 
p.i. and analyzed by Western blot for STAT2, STAT1, pM27, and  -actin. 
(C) pM27 forms a complex with STAT2. STAT2 /  fibroblasts were infected 
with rVV expressing M27FL or STAT2-HA, or coinfected with both viruses 
(3 PFU/cell each). Cell lysates were prepared 8 h p.i. using an EMSA buffer, 
split into two aliquots, and subjected to immunoprecipitation using anti-
HA and anti-FLAG antibodies, respectively. Immunoprecipitates were ana-
lyzed by Western blot for STAT2, pM27, and  -actin.M27 INHIBITS IFN RESPONSES | Zimmermann et al. 1546
STAT1 was marginally down-regulated by all viruses 24 h
p.i., whereas IFN response factor 9 (IRF9)/p48 was not af-
fected (Fig. 3 A). Moreover, protein levels of IRF1, a factor
critically involved in IFN- –induced MHC II expression
and able to activate ISREs (15), were not affected by M27
expression in MCMV-infected cells (Fig. 3 A). The STAT2-
directed effect of pM27 was corroborated by the finding that
the IFN- –induced nuclear accumulation of STAT2 was in-
tact in  M27-MCMV–infected cells but impaired by M27-
HA-MCMV (unpublished data).
To investigate whether the selective expression of pM27
is sufficient to mediate the down-regulation of STAT2, we
expressed the M27-FLAG sequence by a recombinant vac-
cinia virus (rVV), rVV-M27FL. STAT2 was found to be
drastically reduced by rVV-M27FL but not by control VV-
WT. No effect was observed with regard to STAT1 (Fig. 3
B). To test whether there is a physical interaction between
pM27 and STAT2, the proteins were expressed by an rVV,
either alone or together, and immunoprecipitated. A West-
ern blot analysis of immunoprecipitates detected pM27 in
anti-STAT2–precipitated material and vice versa after coex-
pression of both proteins (Fig. 3 C). STAT1 was not found
in the pM27–STAT2 complex (unpublished data). The loss
of STAT2 occurred also in STAT1 /  fibroblasts (reference
16; unpublished data) and thus affects STAT2 monomers,
indicating that the molecular mechanism used by pM27 is
thoroughly different from the parainfluenza virus V protein
that recognizes only STAT1/STAT2 heterodimers (17). The
results demonstrated that STAT2 is the principal and direct
molecular target of pM27.
The proviral effect of pM27 is strictly dependent on STAT2
According to current concepts, STAT1, but not STAT2, is
required for IFNGR signaling (18, 19), although the levels
of STAT1 expression are decreased in STAT2-deficient fi-
broblasts (20). To test whether pM27 has any effect on
STAT1 that does not involve the degradation of STAT1, we
analyzed the IFN- –induced DNA-binding activity of
STAT1 by electrophoretic mobility shift assay (EMSA) in
WT- and STAT2-deficient fibroblasts using a GAS-specific
probe (21). As demonstrated in Fig. 4 A, STAT1 activation
was intact in MCMV-WT and  M27-MCMV–infected
MEFs, excluding the effects of pM27 on STAT1 phosphory-
lation, dimerization, and DNA binding. This held true in
cells lacking STAT2, ruling out the possibility that STAT2
effected STAT1 function (Fig. 4 A). Moreover, the induc-
tion of IRF1 gene expression mediated by STAT1 dimers
( -activated factor) was identical in MCMV-WT– and
 M27-MCMV–infected cells (unpublished data). How-
ever, this result still leaves open the possibility that pM27
causes resistance to IFN-  by acting on a target other than
STAT2. To test whether pM27 is able to block IFNGR-
dependent responses in the absence of STAT2, we studied
MCMV-WT and  M27-MCMV replication in STAT2 / 
fibroblasts (20). As shown in Fig. 4 B, the absence of STAT2
completely abolished the difference between MCMV-WT
and  M27-MCMV, proving that STAT2 is a prerequisite to
demonstrate any effect of pM27 on IFNGR signaling. This
confirmed STAT2 as the only relevant target of pM27 for
IFNGR signaling. Moreover, the reintroduction of STAT2
in STAT2 /  fibroblasts increased the sensitivity of  M27-
MCMV but not MCMV-WT to IFN-  and, importantly,
IFN-  (unpublished data); however, the antiviral capacity of
fibroblasts expressing endogenous STAT2 was clearly supe-
rior, confirming previous findings by Park et al. (20).
The antiviral efficiency of IFN-  is contingent on type I IFN
IFNAR components and IFN-  production were suggested
to enhance IFN-  signaling under certain conditions through
the association of the two non–ligand-binding receptor
chains, IFNAR1 and IFNGR2 (22). To address the possibil-
ity that pM27 disrupts the cross talk between IFNRs by de-
pleting STAT2, we determined the antiviral efficiency of
IFN-  in IFN- –deficient primary MEF (Fig. 5 A). The an-
tiviral efficiency of IFN-  was strongly diminished (Fig. 5
A), but readily restored by the addition of exogenous IFN- 
or IFN-  in a dose-dependent manner (Fig. 5 B). These data
Figure 4. pM27 does not affect STAT1 but requires STAT2 for the 
inhibition of IFN-  responses. (A) C57BL/6 MEFs and STAT2-deficient 
fibroblasts were infected with MCMV-WT or  M27-MCMV (10 PFU/cell 
each) for 24 h and exposed to 200 U/ml IFN-  for 20 min. Equal protein 
amounts from 1:1 mixtures of nuclear and cytoplasmic cell extracts were 
evaluated by EMSA with a GAS probe (reference 21). Supershifting was 
performed by the addition of a STAT1-specific antibody before incubation 
with the probe. The mobility of STAT1 homodimers is indicated. (B) STAT2 /  
fibroblasts were preincubated with 500 U/ml IFN-  for 48 h, or not incu-
bated before infection, with MCMV-WT and  M27-MCMV (0.01 PFU/cell 
each) for the indicated time. Titers of progeny virus were determined by a 
standard plaque assay.JEM VOL. 201, May 16, 2005 1547
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indicate that a substantial part of the antiviral efficiency of
IFN-  depends on a synergistic action with type I IFNs (i.e.,
on IFN-  secretion and IFNAR1 signaling). However, the
synergism of type I and type II IFNs could not explain the
complete proviral effect of pM27. Importantly, in the ab-
sence of type I IFNs, the replication of  M27-MCMV was
still more sensitive to IFN-  compared with MCMV-WT,
reaching 10-fold lower levels of progeny virus (Fig. 5 B).
The fact that IFN-  exerted an antiviral effect on  M27-
MCMV replication in the absence of type I IFN function
led us to conclude that STAT2 must also act as a direct me-
diator of IFN-  responses.
STAT2 activation in response to IFN- 
To assess the capacity of IFN-  to activate STAT2 in the ab-
sence of IFNAR signaling, we analyzed protein phosphory-
lation on tyrosine after the treatment of IFNAR-deficient
MEFs for various times with IFNs (Fig. 6 A). As expected,
IFN-  and IFN-  failed to activate STAT2 in IFNAR1-
deficient cells (Fig. 6 B and not depicted). In infected cells,
STAT1 levels were slightly lower than in uninfected cells,
and IFN- –dependent phosphorylation of STAT1 occurred
in both  M27-MCMV– and in MCMV-WT–infected cells
(Fig. 6 A). Notably, IFN- –induced tyrosine phosphoryla-
tion of STAT2 in IFNAR1-deficient cells was detectable
within 5 min of incubation and increased to higher levels
within 60 min of incubation (Fig. 6 A). The same result was
obtained in  M27-MCMV–infected cells, whereas phos-
phorylated STAT2 was not detectable in MCMV-WT–
infected cells (Fig. 6 A). The induction of STAT2 by IFN- 
did not occur in IFNGR1-deficient cells (Fig. 6 B), proving
that STAT2 activation by IFN-  is indeed coupled to
IFNGR signaling. To test whether IFN-  induces STAT2
phosphorylation in further cells, we analyzed a broad range
Figure 5. MCMV replication in IFN- –deficient cells. (A) Primary 
IFN- –deficient MEFs were infected with MCMV-WT and  M27-MCMV 
(0.01 PFU/cell each). Titers of the infectious virus were determined by a 
standard plaque assay. Growth curves were obtained after 48-h preincu-
bation of cells without IFN, or with 500 U/ml IFN- , 500 U/ml IFN- , or a 
combination of 100 U/ml IFN-  and 100 U/ml IFN- . (B) Primary IFN- –
deficient MEFs were treated with 500 U/ml IFN-  in combination with 
graded concentrations of IFN-  and infected with MCMV-WT and  M27-
MCMV (0.01 PFU/cell each). Viral titers obtained at 96 h p.i. were shown in 
relation to doses of IFN- . The titers in the presence of IFN-  and in the 
complete absence of type I IFN are highlighted by arrows.
Figure 6. Phosphorylation of STAT2 in response to IFN- . (A) Primary 
IFNAR1-deficient MEFs were either mock infected or infected with MCMV-WT 
or  M27-MCMV (10 PFU/cell each) for 24 h before being exposed to 500 U/ml 
IFN-  for the indicated time. Equivalent amounts of cell lysates were sub-
jected to SDS-PAGE and analyzed by Western blot for p-Tyr689 STAT2, and 
reprobed for STAT2, p-Tyr701 STAT1, STAT1, and  -actin. (B) Primary 
IFNAR1- and IFNGR-deficient MEFs were either left untreated or treated 
with IFN-  (100 U/ml and 10 U/ml, respectively) or 500 U/ml IFN-  for 
20 min. Equivalent amounts of cell lysates were analyzed by Western blot 
for p-Tyr689 STAT2 and reprobed for STAT2 and  -actin. (C) NIH 3T3 fibro-
blasts and J774 macrophages were either left untreated or treated with 
50 U/ml IFN-  or 500 U/ml IFN-  for 20 min. 50 NU/ml type I neutralizing 
antibodies were added as indicated to remove endogenously produced IFN- . 
Equivalent amounts of cell lysates were analyzed by Western blot for p-Tyr689 
STAT2, and reprobed for STAT2, p-Tyr701 STAT1, and  -actin. (D) NIH 3T3 
fibroblasts and IFNAR-deficient MEFs were not exposed or exposed to 
500 U/ml IFN-  or 50 U/ml IFN-  for 20 min. Equal protein amounts from 
1:1 mixtures of nuclear and cytoplasmic cell extracts were evaluated by 
EMSA with an ISRE probe (reference 47). Supershifting was performed by 
the addition of a STAT2-specific antibody before incubation with the probe. 
The mobility of ISGF3 is indicated in the right margin.M27 INHIBITS IFN RESPONSES | Zimmermann et al. 1548
of primary cells and cell lines. Although at clearly lower lev-
els when compared with IFN- , IFN-  exposure of NIH
3T3 fibroblasts and J774 macrophages resulted in a rapid
phosphorylation of STAT2 (Fig. 6 C), corroborating earlier
experiments (23). The same type of result was also observed
in BALB/c splenocytes, primary C57BL/6 MEFs, mouse
SVEC endothelial cells, and human MRC5 fibroblasts (un-
published data). To determine whether the IFN- –mediated
activation of STAT2 was sufficient to induce the formation
of ISGF3 complexes and DNA binding, EMSA assays using
an ISRE-specific probe were performed. As demonstrated in
Fig. 6 D, the binding of ISGF3 to ISRE was observed in re-
sponse to IFN-  in NIH 3T3– and IFNAR1-deficient cells,
confirming published data (24). The same result was seen in
 M27-MCMV– but not MCMV-WT–infected cells (un-
published data), proving that IFN-  induced STAT2 results
in ISGF3-mediated signaling.
Considering the relatively low levels of STAT2 activa-
tion reached within 60 min of IFN-  exposure versus the
substantial inhibition achieved during two rounds of  M27-
MCMV replication (Fig. 5), one could surmise that higher
levels of phosphorylated STAT2 were generated during in-
fection. To test this possibility, IFNAR-deficient cells were
analyzed on extended IFN-  treatment (Fig. 7 A). Unlike
mock-infected cells, nucleoplasmic levels of phosphorylated
STAT2 became strongly increased in  M27-MCMV–
infected, IFNAR-deficient cells. Consequently, the formation
and DNA binding of ISGF3 also accumulated over time in
 M27-MCMV–infected, IFN- –exposed, IFNAR1-defi-
cient cells (unpublished data). To assess the antiviral impact
of STAT2 activation in the type I versus type II IFN–medi-
ated inhibition of MCMV replication, we compared the
yield of  M27-MCMV and MCMV-WT replication in
MEFs deficient in STAT2, IFN- , IFNGR, and IFNAR
expressions in the presence of either 500 U/ml IFN-  or
500 U/ml IFN-  at 96 h p.i. As demonstrated previously
(Fig. 4 B), no difference in virus growth was observed for
 M27-MCMV and MCMV-WT when replicating in IFN- –
and IFN- –treated, STAT2-deficient MEFs (Fig. 7 B).
In agreement with the data presented in Fig. 5,  M27-
MCMV replication was  13-fold lower in IFN- –deficient
cells treated with either exogenous IFN-  or IFN-  when
compared with MCMV-WT, demonstrating that STAT2 is
implicated in both the type I and type II IFN pathways.
IFN-  treatment of IFNAR-deficient cells did not influence
 M27-MCMV growth when related to MCMV-WT repli-
cation, whereas IFN-  blocked  M27-MCMV   20-fold
better than MCMV-WT (Fig. 7 B). The enhanced inhibi-
tion of  M27-MCMV by IFN-  was abolished in IFNGR-
deficient cells, but evident when using IFN-  (Fig. 7 B).
Considering that pM27 exclusively affects STAT2, these
data demonstrate that both types of IFNs require STAT2 to
block MCMV replication. In summary, the findings establish
a STAT2- and ISGF3-dependent pathway of IFN-  signal-
ing for antiviral responses.
M27 is essential for MCMV replication in vivo, and 
replication of  M27-MCMV is restored in IFNAR- and 
IFNGR-deficient mice
To evaluate the significance of M27 in vivo,  M27-MCMV
and M27rev virus titers were determined in the major target
organs of C57BL/6 (Fig. 8 A) and 129/Sv (unpublished
data) mice. M27rev replicated in all tissues, reaching peak ti-
ters in the liver at 7–14 d and in the SGs at day 14, before
MCMV growth was cleared in all organs except the SGs. In
contrast,  M27-MCMV did not replicate in the liver and
did not spread to the SGs. Thus, the deletion of M27 re-
sulted in a dramatic replication deficiency of MCMV in
vivo, confirming published data (14). To dissect the relative
impact of STAT2 activation by IFN  /  and IFN-  in
vivo, we studied the absence of the M27 expression in
MCMV-infected IFNGR- and IFNAR-deficient mice. If
the attenuated phenotype was because of a STAT2-depen-
dent effect on IFNAR as well as IFNGR signaling, it is
reasonable to assume that  M27-MCMV should replicate
to higher titers in mice lacking IFNGR (25) and IFNAR,
at least during the first days of infection before the onset
of adaptive immunity. Replication of  M27-MCMV in
IFNGR1-deficient mice reached titers in the liver compara-
ble to those seen with M27rev at day 3 p.i. in C57BL/6
mice. Thereafter,  M27-MCMV was rapidly cleared in
Figure 7. IFN- –induced increase of STAT2-P in  M27-infected 
cells and its impact for the inhibition of MCMV replication. (A) IFNAR1-
deficient MEFs were either mock infected or infected with  M27-MCMV 
or MCMV-WT (10 PFU/cell each) for 24 h before exposed to 500 U/ml 
IFN-  for the indicated time. Equivalent amounts of nucleoplasmic lysates 
were subjected to SDS-PAGE and analyzed by Western blot for p-Tyr689 
STAT2, and reprobed for STAT2 and  -actin. (B) Comparative analysis of 
MCMV replication in MEF lacking components of the IFN signaling cas-
cade. The indicated cells were incubated with 500 U/ml IFN-  or 500 U/ml 
IFN-  for 48 h or left untreated before being infected with MCMV-WT or 
 M27-MCMV (0.01 PFU/cell each). The efficiency of MCMV replication is 
expressed as the ratio of virus yield at 96 h p.i., as determined by a stan-
dard plaque assay.JEM VOL. 201, May 16, 2005 1549
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IFNGR1-deficient mice but able to spread to the SGs (Fig. 8
B). The data suggest that control of  M27-MCMV in IFNGR-
KO mice is mediated through a STAT2-dependent pathway
of type I IFN that is intact in IFNGR-deficient mice but
blocked by M27rev. Likewise,  M27-MCMV, but not
MCMVrev, was rapidly cleared in IFNAR1-deficient mice
after an initial phase of replication at day 3 p.i and failed to
establish an infection in the SGs (Fig. 8 C), which is compat-
ible with an IFN- –mediated control of viral replication de-
pending on STAT2. In summary, replication in the initial
stages of infection in mice correlated with the relative pro-
ductivity of  M27-MCMV and M27rev observed in IFN-
treated, IFNR-deficient fibroblasts (Fig. 7 B), although the
relative usage of individual IFN pathways cannot be assessed
in vivo. At later stages,  M27-MCMV replication was con-
trolled in both IFNAR1 and IFNGR1-deficient animals,
whereas M27rev replicated to very high titers in all organs
(Fig. 8, B and C).
In a further set of experiments, higher virus doses were
administered intravenously. Under these conditions, M27rev
caused a lethal infection in 90% of IFNAR1-deficient mice
and  50% of IFNGR1-deficient mice (Fig. 8 D), respec-
tively, confirming previously published data (7). Deletion of
M27 resulted in the complete survival of both IFNAR1- and
IFNGR1-KO mice, indicating that STAT2-dependent
functions induced by IFN-  or type I IFNs can protect
against lethal infection in vivo.
DISCUSSION
Based on a systematic approach of forward mutagenesis using
the random transposon insertion into a CMV–BACmid and
the screening of mutants with an IFN-sensitive reporter
gene, this study identifies the long sought after CMV antag-
onist of IFNR signaling. The Tn insertion found in three in-
dependent mutants guided the search to a single gene, M27,
as a causal principle. This gene is conserved between all
 -herpesvirinae. Remarkably, we discovered that the M27-
encoded, 79-kD protein blocked both IFN- /  and IFN- 
responses via STAT2 and, thus, has a huge impact on viral
fitness in vivo. The selective removal of the STAT2 protein
by pM27 is executed via the ubiquitin–proteasome pathway
of protein degradation (unpublished data). In this study, we
took advantage of a panel of targeted, single gene KO host
cells and used pM27 as a selective tool to allow the dissection
of STAT2-dependent antiviral effects. This combined ap-
proach provided the unique opportunity to assess the relative
impact of IFNs and their intracellular signal transduction
pathways with regard to their antiviral potency.
pM27 substrate specificity
According to the current understanding, STAT1, but not
STAT2, has a central role in both IFNAR and IFNGR sig-
naling (2, 4, 18, 19, 26). The inhibition of STAT1, which
represents a common component between the IFN- /  and
the IFN-  signaling pathways, is an obvious strategy for a vi-
rus that causes infected cells to resist the action of IFNs re-
gardless of whether the IFNs were produced by infected cells
or activated immune cells. Indeed, several viruses, including
members of Paramyxoviridae, follow this principle (26).
Therefore, the specificity of pM27 for its cellular target,
STAT2, deserves comment. Considering the relative resis-
tance of MCMV replication against IFN-  and IFN-  con-
ferred by pM27, our findings come as a surprise. Most indi-
cators reveal that pM27 has an exquisite specificity for
monomeric STAT2, but not for STAT1, supported by evi-
dence such as: (a) both mouse and human STAT2, but not
STAT1, were down-regulated; no effect was seen with re-
gard to STAT3 and STAT4 (unpublished data), which have
also been implicated in IFNR signaling (for review see refer-
ence 19); (b) pM27 forms a physical complex with STAT2
but not STAT1; (c) the nuclear accumulation of STAT2,
but not STAT1, was affected (unpublished data); (d) the
IFN- –induced DNA-binding activity of STAT1 was intact
in MCMV-infected fibroblasts; and (e) most important,
 M27-MCMV replicates as efficiently as MCMV-WT in
response to IFN-  in STAT2-deficient fibroblasts (Fig. 5 B),
indicating that the proviral activity of pM27 depends exclu-
Figure 8. Analysis of  M27-MCMV and M27rev in vivo. (A) C57BL/6, 
(B) 129Sv(ev) IFNGR1 /  mice (reference 25), and (C) IFNAR1 /  mice 
backcrossed with C57BL/6 mice were infected i.p. with 2   105 PFU of 
tissue culture–derived  M27-MCMV or M27rev. Mice were killed at days 
3, 7, 14, and 21, and organ titers of  M27-MCMV or M27rev in the liver 
and SGs were determined by a standard plaque assay. Each value represents 
the median of total SG titers or 1 g of liver from five infected animals. The 
dotted line shows the detection limit of organ titration ( 100 PFU/gram 
of organ). (D) IFNAR1 /  and IFNGR1 /  mice (n   10 per group) were 
infected i.v. with 5   106 PFU of the indicated virus and monitored for 
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sively on STAT2 expression. A moderate decrease of
STAT1 protein levels in MCMV-infected cells occurred in-
dependently of M27, pointing to an additional viral function
undermining IFN responsiveness.
STAT2 activation by IFN- 
STAT2 has a well-established role as an essential mediator of
signal transduction through the type I IFNR because of its
incorporation into ISGF3 complexes (19, 20, 26). Our find-
ings provide several lines of evidence indicating that STAT2
plays an additional role after triggering the IFNGR. First,
STAT2 is activated by IFN-  in a broad range of cell types,
as indicated by tyrosine phosphorylation. Second, STAT2 ac-
tivation is abolished in IFNGR-deficient cells. Third, IFN- 
induces ISGF3 complex formation and DNA binding.
Fourth, IFN-  exerted a pM27-dependent antiviral activity
when acting in the complete absence of type I IFNs (i.e., in
IFNAR1-deficient and IFN- –deficient cells). Fifth, cellular
genes known to be activated by IFN-  (e.g., the immuno-
proteasome subunits LMP2, LMP7, and MECL1) are induc-
ible in  M27-MCMV–infected, but blocked in MCMV-
WT–infected, cells (27). And sixth, MCMV replication and
the outcome of infection in IFNAR1-deficient mice (with
intact IFNGR expression) were dependent on pM27, sug-
gesting that STAT2 plays a decisive antiviral role for IFNGR-
mediated responses in vivo. Notably, our findings are not
completely unprecedented. A previous study reported an im-
paired inhibition of vesicular stomatitis virus replication by
IFN-  in STAT2-deficient cells (20). This result was inter-
preted to be caused by an impaired autocrine loop in which
IFN-  promotes its antiviral activity by the induction of type
I IFNs (20). Based on our finding that STAT2 activation in
response to IFN-  occurs within minutes, we can exclude
this explanation. The fact that IFN-  induces STAT2 phos-
phorylation in many types of cells (Fig. 7 B), raises the possi-
bility that this signaling pathway is of broad significance for
various tissues and is critical for the control of a variety of vi-
ral pathogens. Clearly, further components of this IFNGR-
coupled signaling pathway remain to be elucidated (e.g., the
IFNGR-associated tyrosine kinase[s], which recognize
STAT2 as a substrate). One candidate kinase is represented by
JAK1, which is associated with IFNGR and was demon-
strated to be able to mediate tyrosine phosphorylation of
STAT2 when expressed in insect cells (28).
It is self-evident that the different degrees of STAT2 ac-
tivation by type I versus type II IFN cannot simply be trans-
lated into its relative antiviral effectiveness. IFN-  generates
relatively low levels of activated STAT2 in normal cells,
which explains why this pathway escaped attention in the
past. Guided by a clear pM27- and STAT2-dependent phe-
notype of MCMV replication, we discovered high levels of
phosphorylated STAT2 in  M27-MCMV–infected cells
within hours of IFN-  exposure without any involvement
of IFNAR signaling (Fig. 7 A). At first glance, the activation
of STAT2 by IFN- , resulting in ISGF3 formation, might
appear simply redundant with the stronger induction of this
transcription complex by type I IFNs. Instead, the intrinsic
capacity of IFNGR to induce not only STAT1 dimers, but
also STAT2 phosphorylation and thus ISGF3 autonomously,
is of great biological advantage. A large number of viruses,
including HCMV (29) and many RNA viruses, are able to
repress the transcriptional activation of type I IFN genes, and
poxviruses prevent the binding of secreted type I IFNs to
IFNAR (26). Such countermeasures foil the attempt to induce
ISGF3; i.e., the autocrine loop of type I IFNs enhancing
IFN- . In such a scenario, ISGF3 activation by IFN- , even
at lower levels, may provide a substantial qualitative, as well
as a quantitative, augmentation of IFNGR/GAS-driven
transcriptional responses and represent a decisive adaptive
strategy of the antiviral defense. As demonstrated in MCMV-
infected, IFNAR-deficient mice, this antiviral mechanism
can protect from lethal disease (Fig. 8 D). On the other
hand, IGSF3 becomes an attractive target for viral interfer-
ence because it is of utmost importance for IFNAR as well
as IFNGR signaling. Remarkably, HCMV shares this strat-
egy with MCMV by down-regulating the third component
of ISGF3, IRF9/p48 (30).
The proviral effect of pM27 on MCMV replication was
particularly prominent in cells pretreated with high doses of
IFNs; i.e., after the complete activation of the IFN-mediated
pathways and the establishment an antiviral state. From this
observation, we must conclude that the maintenance of the
antiviral state critically requires an intact and permanent
function of STAT2. This implies that the antiviral state, by
itself, is not a long-lasting biological condition but is readily
reversed when IFNR signaling is disrupted.
pM27 disruption of type I and type II IFN synergy
Another prominent finding of our study is the fact that IFN- 
relies in part on type I IFNs to achieve a potent antiviral re-
sponse. This effect requires only minute amounts of type I
IFNs (Fig. 5) and may explain the antiviral synergism that
has been observed with other herpesviruses like HSV (31).
The required levels of IFN- /  are easily achieved either by
virus induction and/or by IFN-  itself, which induces type I
IFNs (32). In fact, the antiviral activity of IFN-  in cells
with the capacity to establish the autocrine type I IFN loop
may generally include the synergistic effect of type I IFNs.
Only the complete withdrawal of any IFN- /  secretion or
the prevention of signaling (e.g., in IFNAR-deficient cells)
discloses the relatively weak antiviral response exerted by
IFN-  alone. Therefore, although the disruption of STAT2
by pM27 only demonstrates a moderate effect with regard to
the antiviral potency of type I IFNs, it has much more dra-
matic consequences for the antiviral efficiency of IFN- .
The augmentation of type II by type I IFNs is unidirec-
tional, as the IFN- –mediated inhibition in IFNGR1-defi-
cient cells is not affected (22, 27).
According to classical concepts, IFNAR and IFNGR
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each activating a specific set of STAT proteins (2, 4, 18, 19).
Several explanations for the IFN synergy observed here are
possible. The cross communication of both IFNs could op-
erate as molecular cross talk between non–ligand-binding
IFNR components (i.e., IFNAR1 and IFNGR2), which
were proposed to directly interact in caveolar membranes
and thus couple both receptor pathways (22). There is evi-
dence that STAT2 as well as STAT1 are indeed physically
associated with IFNAR1 and IFNGR2 after IFN-  treat-
ment (22), providing a possible pM27 checkpoint to inter-
fere with. In addition, the synergy between both pathways
may be achieved at a transcriptional level by potentiating the
transcriptional activation of antiviral genes because of a con-
certed action of  -activated factor and ISGF3.
By using pM27 to attack a single molecular target, STAT
2, MCMV performs the dual function of withstanding type I
and type II IFNs. By depleting STAT2, pM27 gains control
over IFNR signaling by (a) disrupting IFNAR signal trans-
duction; (b) preventing the synergy of type I IFNs with IFN- ,
which is of primary importance for MCMV replication; and
(c) blocking the downstream signals induced by a direct acti-
vation of STAT2 by IFN- . In addition, pM27 may even af-
fect GAS-dependent responses by reducing the expression
level of STAT1, which is controlled by STAT2 (20).
Consequences of M27 expression for MCMV immunity
Besides its direct activity in promoting virus replication in the
presence of IFNs, pM27 is also likely to have immunomodu-
latory proviral effects. IFN-  stimulates a multitude of genes
implicated in antigen presentation, cell adhesion, chemotaxis,
and inflammation (33). In fact, the antiviral effector function
of both CD8  and CD4  T cells depends critically on IFN- 
(5, 8, 34). Replicating under the permanent and selective
pressure of IFNs, CMVs have developed gene functions that
counteract IFN-induced gene expression. CMV-infected
cells were shown to resist IFN- –induced MHC class II ex-
pression, transcriptional activation, and antigen presentation
to CD8  T cells (8, 10, 12, 35-37). Therefore, it is conceiv-
able that  M27-MCMV–infected cells differ from M27-
expressing cells with regard to antigen presentation. In fact, the
expression of IFN- –inducible proteasome subunits, which is
prevented in MCMV-WT infected cells, is at least partially
restored in the absence of M27 (27). Such differences may
explain our observation that the initial restoration of  M27-
MCMV replication in IFNR-deficient mice is rapidly cleared
at later time points of infection when T cell responses are
mounted. Conversely, M27-expressing MCMV achieves a
sustained phase of replication, demonstrating that STAT2
constitutes an important target whose selection is required to
gain a window of opportunity for viral replication and spread
in an IFN-producing environment.
MATERIALS AND METHODS
MCMV infection of mice and plaque assay for the detection of
MCMV in tissues.  C57BL/6 and IFNAR1 /  (provided by S.H.E.
Kaufmann, Max-Planck-Institute for Infection Biology, Berlin, Germany)
backcrossed with C57BL/6 mice and IFNGR1 /  mice (25) were bred in
the Central Animal Facility of Rijeka University, in accordance with the
guidelines contained in the International Guiding Principles for Biomedical
Research Involving Animals. The Ethical Committee at the University of
Rijeka approved all animal experiments. 6–8-wk-old mice were infected
i.p. with 2   105 PFU of tissue culture–derived  M27-MCMV or M27rev
diluted in a volume of 500  l. Mice were killed at day 3, 7, 14, or 21 p.i.,
and the organs were frozen immediately at –70 C. The titer of infectious
virus was determined by titrating organ homogenates of liver and SGs using
a standard plaque assay (6).
Cells.  Primary MEFs of C57BL/6, IFNAR1 / , IFNGR1 / , or IFN-
  /  mice (provided by T. Leanderson, Lund University, Lund, Sweden;
reference 38) were prepared as previously described (39). MEFs were main-
tained in DMEM supplemented with 10% FCS, penicillin, and streptomy-
cin, and 2 mM glutamine, and they were used for subsequent experiments
within three passages. Murine STAT1 /  cells (provided by D. Levy, New
York University School of Medicine, New York, NY; reference 16),
SVEC (CRL-2181), J774 macrophages (TIB-67), human MRC-5 fibro-
blasts (CCL-171; all three from American Type Culture Collection), and
CV1 cells were grown in DMEM with 10% FCS. For the culture of NIH
3T3 (CRL1658; American Type Culture Collection), 3T3-ISRE-luc cells
(provided by E. Hellebrand, Max von Pettenkofer-Institut, Munich, Ger-
many) and STAT2 /  fibroblasts (provided by C. Schindler, Columbia
University, New York, NY; reference 20), FCS was replaced with 5% nor-
mal calf serum.
Viruses, IFN conditions, and virus replication analysis.  The
MCMV-WT viruses used were either MCMV strain Smith or the BAC-
derived WT recombinant MW97.01 with WT properties in vitro and in
vivo (40). Viable MCMV random Tn insertion mutants were retrieved
from a library of TnMax16 containing MCMV BACs after the transfection
of NIH 3T3 cells (13). The Tn insertion site was determined by DNA se-
quencing as described previously (41). Virus stocks were prepared and virus
titers were measured by a standard plaque assay on MEFs. MCMV infection
was enhanced by centrifugation at 800 g for 30 min. The selective expres-
sion of MCMV immediate early gene products was achieved as described
previously (8). Late phase gene expression was prevented by 250  g/ml
phosphonoacetic acid. For the replication analysis, MEFs in passage 2 were
infected with 0.01 PFU/cell MCMV and frozen at –70 C at the time points
indicated in Figs. 2 A, 4 B, and 5 A. Susceptibility to IFNs was assayed by
virus growth in the presence of recombinant mouse IFN-  or IFN-  (PBL
Biomedical Laboratories) after preincubation with IFNs for 48 h before in-
fection. In some experiments, type I IFN neutralizing antibodies (PBL Bio-
medical Laboratories) were used. The infection of subconfluent 3T3 or
STAT1 /  cells with VV was performed overnight with 5 PFU/cell. VV
titers were measured by plaque assay on CV1 cells.
BAC-based mutagenesis and construction of recombinant MCMV
viruses.  Recombinant MCMV were generated according to a previously
published procedure (42) using the BAC plasmid pSM3fr (40). For the con-
struction of the  M27-MCMV mutant, a PCR fragment was generated
from the contiguous primers 5 -M27 (5 -ATATTCCTCCTGTCTTCC-
GTGTGTCGCTCGTGTCCTGTCACGTCGTGGAATGCCTTCGA-
TTC-3 ) and 3 -DEL-M27 (5 -GGAAAAAGACGACGGTGTCATTTA-
TCGACGGCGCCGTGTCGCGCTGACCACAAGGACGACGACGA-
CAAGTAA-3 ) using the plasmid pSLFRTKn (43) as template DNA. For
the 3 -terminal addition of the HA-tag sequence to the M27 ORF, a PCR
fragment was generated using the same template and the primers 5 -M27
and 3 -M27-HA(5 -GATGATGGCGGCGAGTCCGACGGCTCCGA-
GTTTGTGGTGGAGCGGGTGTACCCATACGATGTTCCAGATTA-
CGCGTGAACAAGGACGACGACGACAAGTAA-3  (HA sequence
underlined). The PCR fragments containing a kanamycin resistance gene
were inserted into pSM3fr by homologous recombination in Escherichia coli,
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The Knr was excised from both BACs by FLP-mediated recombination
(42), generating the MCMV BACs pSM3fr-M27HA and pSM3fr- M27.
The M27rev virus was constructed from a 5.2-kb KpnI fragment (nt
30293–35480) containing the M27 gene and flanking homologies sub-
cloned into the shuttle vector pST76KSR (provided by M. Messerle, Han-
nover Medical School, Hannover, Germany). The M27 gene from plasmid
pST76KSR-M27 was inserted into pSM3fr- M27 by two-step homolo-
gous recombination (44), resulting in the BAC pSM3fr-M27rev. The cor-
rect mutagenesis of all recombinant MCMV BACs was confirmed by a re-
striction analysis and the sequencing of the M27 genome region. The
recombinant viruses  M27-MCMV, M27HA, and M27rev were reconsti-
tuted by the transfection of MEF using Superfect reagent (QIAGEN). Re-
sidual BAC sequences were removed by sequential cell culture passages as
previously described (40).
Generation of VV recombinants (rVV).  The  M27 ORF was ampli-
fied from MCMV using the primers az-M27-1 (5 -CTCTCTAGATCT-
GACCATGGCGGACCG-3 ) and az-M27-F2 (5 -CACAGAATTCTGC-
AGTCACTTGTCGTCGTCGTCCTTGTAGTCCACCCGCTCCACC-
ACAAACTC-3 ). Primer az-M27-1 contains a BglII site (in italics), and az-
M27-F2 contains an EcoRI site (in italics) and the coding sequence for the
FLAG epitope (underlined). The PCR fragment was cloned into the vaccinia
expression vector p7.5k, resulting in p7.5K131-M27FL, which was used to
generate rVVM27FL after homologous recombination into the thymidine ki-
nase locus of vaccinia strain Copenhagen as described previously (45). For the
generation of rVVSTAT2HA, the STAT2 gene was subcloned from pRC-
STAT2 (a gift from C. Schindler) into p7.5K131. The HA tag was added us-
ing the primers az-STAT2-1 (5 -TTCCTCTATCCCCGAATCCCTC-3 )
and az-STAT2-HA2 (5 -CGGGGTACCTCACGCGTAATCTGGAACA-
TCGTATGGGTACGCAGCGTCCTTAGAAGGTATCAAGAG-3 ) con-
taining the HA coding sequence (underlined). The rVVs were isolated by se-
lection with BrDU using tk  143 cells.
Reporter gene assays.  3T3-ISRE-luc cells were selected after cotrans-
fection with pcDNA1-neo (Invitrogen) and pISRE (Stratagene) containing
five copies of an ISRE consensus sequence upstream of the firefly luciferase
gene, and then cultured in the presence of 100  g/ml G418. For reporter
gene assays, either uninfected cells or MCMV-infected cells (10 PFU/cell)
were induced with recombinant mouse IFN-  for 5 h and harvested in lysis
buffer. Luciferase activity was then measured according to the manufac-
turer’s instructions (Roche) using a microplate luminometer (model LB 96
V; Berthold).
EMSA, immunoblot analysis, and immunoprecipitation. Extrac-
tions were performed according to established protocols (46). Cells were in-
fected (10 PFU/cell) and washed before being lysed in cytosolic extraction
buffer (10 mM KCl, 20 mM Hepes, 0.2% NP-40, 0.1 mM EDTA, 10%
glycerol, 0.1 mM vanadate, 0.1 mM PMSF, 1 mM dithiothreitol, and com-
plete protease inhibitors, pH 7.4; Roche). The extracts were spun at 16,000 g
for 16 s at 4 C. The supernatants were collected, spun for 10 min, and
used as cytosolic extracts for EMSA and immunoblot. The pellets were
washed in PBS and suspended in nuclear extraction buffer (420 mM KCl,
20 mM Hepes, 0.1 mM vanadate, 20% glycerol, 1 mM EDTA, 0.1 mM
PMSF, 1 mM dithiothreitol, and complete protease inhibitors, pH 7.6). Af-
ter incubation on ice for 30 min, the extracts were spun at 16,000 g for 20
min at 4 C, and the supernatants were used as nuclear extracts. A 1:1 mix of
nuclear and cytosolic lysate was incubated with 1 ng of 32P-labeled M67
GAS (21) or ISG15 ISRE probe (47) for 5 min at room temperature. The
binding activity was visualized by a phosphoimaging system (model Storm
820; Molecular Dynamics). The supershift was performed with rabbit anti-
serum recognizing STAT1 (E23; Santa Cruz Biotechnology, Inc.) or mu-
rine STAT2 (20).
For immunoblotting, equal amounts of cell lysate were suspended in a
Laemmli sample buffer. Proteins were separated by SDS-PAGE and trans-
ferred to nitrocellulose filters. Immunoblot analyses were performed with
anti-HA–specific rat mAb 3F10 (Roche), anti-FLAG–specific mouse mAb
M2 (Sigma-Aldrich), monoclonal mouse anti– -actin (Sigma-Aldrich),
mouse mAb raised against MCMV pp89 (CROMA 101), rabbit antiserum
specific for STAT1 (E23) or murine STAT2 (provided by C. Schindler; ref-
erence 20), antiserum against IRF9/p48 (C20; Santa Cruz Biotechnology,
Inc.), IRF1 (M20; Santa Cruz Biotechnology, Inc.), and mAb recognizing
p-Tyr701 STAT1 (A2; Santa Cruz Biotechnology, Inc.) or p-Tyr689 STAT2
(Tyr 689; Upstate Biotechnology). Proteins were visualized using the ECL-
Plus chemiluminescence system (GE Healthcare). Immunoprecipitation was
performed as previously described (48) using anti-HA or anti-FLAG anti-
bodies after cell lysis using EMSA buffer.
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